Article

Emerging SARS-CoV-2 Variant B.1.1.7 Reduces Neutralization Activity of Antibodies Against Wild-Type SARS-CoV-2

2021-06-25

Abstract excerpt

Abstract: Spike-specific antibodies contribute significantly to the neutralizing activity against SARS-CoV-2 and are important for the therapeutic effect of convalescent plasma. B.1.1.7 is a recently emerged variant of SARS-CoV-2 that has several mutations in the gene encoding for the spike-protein. To assess the potential effect these mutations could have on the neutralizing efficacy of antibodies, we evaluated 9...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 705a4778-3e16-51e1-af48-96fe8e3dfbd7
DOI: 10.2139/ssrn.3852736

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Emerging SARS-CoV-2 Variant B.1.1.7 Reduces Neutralization Activity of Antibodies Against Wild-Type SARS-CoV-2DOI 10.2139/ssrn.3852736Read

Decline of humoral responses against SARS-CoV-2 Spike in convalescent individualsSemantic proximity Read

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodiesSemantic proximity Read

Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineageSemantic proximity Read

Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage.Semantic proximity Read

Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spikeSemantic proximity Read

Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients.Semantic proximity Read

Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies.Semantic proximity Read

Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.Semantic proximity Read

Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 InfectionSemantic proximity Read

Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 <i>In Vitro</i> Virus Neutralization in Convalescent PlasmaSemantic proximity Read

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal AntibodiesSemantic proximity Read

Convalescent plasma anti–SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralizationSemantic proximity Read